Developer docs
API playgroundTry for free, no card

Search company profiles

GreenBone Ortho

Full company profile

uuid0002k7j

Namestring
GreenBone Ortho
Legal namestring
GREENBONE ORTHO SPA
Websiteurl
greenbone.it
Company typeenum
Private
Founded yearint
2015
Descriptiontext

GreenBone Ortho S.p.A. is an Italian medical device company headquartered in Faenza with manufacturing in Roncadelle, founded in 2014-2015 to commercialize bone graft substitute technology originating from research at ISTEC-CNR (Institute of Science and Technology for Ceramics – National Research Council). The company's sole commercial product is b.Bone, a CE-marked, ISO 10993-compliant bone substitute derived from rattan wood through a patented multi-step biomorphic transformation process that converts the natural wood structure into an inorganic hydroxyapatite/beta-tricalcium phosphate scaffold. The biomimetic 3D porous architecture preserves ion-doped bone-like chemistry (CO32-, Mg2+, Sr2+) and supports osteoinductive bone regeneration, with the product offered in four form factors (cylinders, blocks, wedges, granules) for traumatology, bone augmentation, deformity correction, non-union, osteotomy, and joint revision applications.

The business model is hardware sales of b.Bone medical devices through a hybrid channel: direct field sales to orthopedic surgeons and hospitals supported by clinical evidence generation, plus regional distribution partnerships — Abiogen Pharma and Mikai in Italy, and Endocon for Germany and Austria since September 2024. The company sells to orthopedic and trauma surgeons at hospital procurement level, with its clinical value proposition positioned against autograft (eliminating donor site morbidity) and conventional synthetic bone substitutes. Revenue is not publicly disclosed. The company has raised approximately €27.5 million in equity and non-dilutive funding from META Ventures, Italian Angels for Growth, Innogest Capital, 3B Future Health Fund, CDP Venture Capital, Invitalia Ventures, the European Innovation Council, and a Regione Lombardia grant.

The company is pursuing geographic expansion (DACH, with UK clinical study activity) and indication extension, most notably via the May 2026 AstroBone experiment on the International Space Station — a partnership with ESA, ASI, San Martino Hospital, and the University of Genoa — to test b.Bone behavior in microgravity for osteoporosis treatment. Patient-specific custom-made implants are in development under the Fast-Tech grant. The company holds 11-50 employees, is privately held, and is led by CEO Saverio Gellini with a management team drawn from Medtronic, Invatec, and other medical device backgrounds.

Short descriptiontext

GreenBone Ortho S.p.A. is an Italian medical device company that develops and commercializes b.Bone, a CE-marked biomimetic bone graft substitute made by biomorphically transforming rattan wood into a hydroxyapatite/beta-tricalcium phosphate scaffold. It sells to orthopedic and trauma surgeons and hospitals across Italy, Germany, and Austria via distribution partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRoncadelle, Italy
HQ citystring
Roncadelle
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bone graft substitute, orthopedic medical devices, biomimetic bone implants, bone regeneration scaffolds, hydroxyapatite bone substitute
Industry2 codes
PRIMARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
NAICS code2 codes
  • Dental Equipment and Supplies Manufacturing339114
  • Dental Laboratories339116
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Dental Equipment & Supplies3843
Product category
Orthopedic Bone Regeneration Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1b.Bone Bone Substitute Products
TypeHardware Sales
Description

GreenBone Ortho generates revenue through the sale of its b.Bone biomimetic bone substitute products, which are available in multiple forms including cylinders, blocks, wedges, and granules. The products are sold to hospitals and orthopedic surgeons for bone regeneration procedures.

greenbone.it
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1b.Bone
Description

Innovative biomimetic bone substitute product derived from rattan wood through a patented biomorphic transformation process. CE-marked medical device for bone regeneration in orthopedic procedures.

greenbone.it
Core offering1 text field

GreenBone Ortho manufactures and sells b.Bone, an innovative biomimetic and bioactive bone substitute derived from rattan wood through a proprietary biomorphic transformation process. The product is composed of hydroxyapatite and beta-tricalcium phosphate in a highly interconnected porous 3D structure that mimics natural human bone architecture. It is available in four form factors (cylinders, blocks, wedges, granules) for orthopedic applications including traumatology, bone augmentation, deformity correction, bone lengthening, non-union treatment, osteotomy, and joint revision.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 75% average bone healing rate at 12 months in LongBone clinical study
+4 more records
Product overview1 text field

GreenBone Ortho's core offering is the b.Bone product line, a family of biomimetic bone substitute scaffolds derived from rattan wood through a proprietary multi-step biomorphic transformation process. The product portfolio includes four main form factors (cylinders, blocks, wedges, and granules) designed for various orthopedic clinical applications including traumatology, bone augmentation, correction of deformity, bone lengthening, non-union treatment, osteotomy, and joint revision. The technology transforms natural rattan wood into inorganic biomaterial while preserving its hierarchical architecture, creating scaffolds that promote new bone formation and remodeling.

Product and service1 record
1b.Bone Bone Substitute
CategoryOrthopedic Bone Regeneration Medical Devices
Description

b.Bone is an innovative biomimetic and bioactive bone substitute derived from rattan wood through a proprietary biomorphic transformation process. It is composed of hydroxyapatite and beta-tricalcium phosphate in a highly interconnected porous 3D structure that mimics the hierarchical architecture of natural human bone. Available in cylinders, blocks, wedges, and granules, it is used by orthopedic and trauma surgeons for bone regeneration procedures including traumatology, bone augmentation, deformity correction, bone lengthening, non-union treatment, osteotomy, and joint revision.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
1Endocon
Strategic tierKeyTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-09-10
Description

Strategic partnership formed September 2024 to bring GreenBone's bone substitute to Germany and Austria. Endocon has deep expertise and strong network in the orthopedic sector.

greenbone.it
Strategic tierKeyTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-02-09
Description

Italian distribution partner announced February 2024 for long-term partnership to distribute GreenBone's innovative bone substitute in the Italian market.

Strategic tierKeyTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-05-01
Description

Italian distribution partner for b.Bone bone substitute products. Agreement signed May 2022 for distribution in Italian market. Abiogen is specialized in orthopedic and healthcare products.

4ISTEC-CNR (Institute of Science and Technology for Ceramics – National Research Council)
Strategic tierFoundationalTypeStrategic or Co-development Partner
Description

Research institution in Faenza, Italy where the original biomorphic transformation technology was developed by Dr. Anna Tampieri and her team. Dr. Tampieri continues as Board Member of GreenBone.

greenbone.it
Strategic tierProjectTypeTechnology or Integration
Description

Designed and built the sixteen experiment units housing b.Bone scaffold for ISS space experiment. Provided essential infrastructure for survival, growth and monitoring of mesenchymal stem cells in microgravity.

Strategic tierProjectTypeStrategic or Co-development Partner
Description

European Space Agency partnered with GreenBone for AstroBone experiment on International Space Station to test b.Bone behavior in microgravity conditions for osteoporosis research.

7ASI (Agenzia Spaziale Italiana)
Strategic tierProjectTypeStrategic or Co-development Partner
Description

Italian Space Agency supporting the AstroBone project alongside ESA for testing b.Bone on ISS for osteoporosis treatment validation.

greenbone.it
8INBAR (International Bamboo and Rattan Organization)
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Intergovernmental organization collaborating with GreenBone to promote local partnerships for rattan nursery and proprietary plantations, ensuring environmental sustainability of raw material sourcing.

greenbone.it
9Clinica Mobile
Strategic tierMinorTypeGTM or Marketing Partner
Description

Worldwide partnership announced February 2021 with MotoGP and SuperBike medical team, bringing GreenBone bone substitute to professional motorsport for potential orthopedic applications.

greenbone.it
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Orthofix Medical offers bone growth stimulation devices and orthobiologics (Trinity Elite allograft, FIBERGRAFT) for spine and orthopedic trauma. Closely comparable to GreenBone as a specialty orthobiologics competitor with overlapping indications and channel model.

TypeBroad incumbent
Description

Smith+Nephew markets bone graft substitutes including MAGNEZIUM and HEALOS through its Orthopaedics franchise. Large incumbent with global commercial reach that overlaps with GreenBone's European trauma and reconstruction target indications.

TypeBroad incumbent
Description

Stryker's Orthopaedics and Spine segments sell Vitoss, OP-1 Putty, and other bone graft substitutes. Large incumbent with established trauma and reconstructive surgery sales channels that compete head-to-head with b.Bone in hospital procurement cycles.

TypeBroad incumbent
Description

Bioventus is an established orthobiologics company offering bone graft substitutes (including SIGNAFUSE, OSTEOAMP) and osteoarthritis pain treatments. Broader incumbent portfolio overlapping directly with GreenBone's bone graft substitute category, with deeper commercial reach.

TypeDirect peer
Description

Curasan is a German specialty orthobiologics company marketing synthetic bone graft substitutes (Cerasorb) for dental and orthopedic indications. European mid-cap comparable to GreenBone in size, product type, and commercialization stage.

TypeDirect peer
Description

Bonesupport is a Swedish orthobiologics company commercializing CERAMENT, an injectable bone void filler for trauma and orthopedic applications. Directly comparable to GreenBone as a European specialty bone graft substitute player with a single differentiated synthetic technology and CE-marked commercial product.

TypeBroad incumbent
Description

MTF Biologics is a major US tissue bank providing allograft-based bone graft substitutes (including Trinity Evolution, Map3) for orthopedic and sports medicine. Competes with GreenBone in the same orthopedic indications via allograft rather than synthetic route.

TypeBroad incumbent
Description

Zimmer Biomet offers a broad orthobiologics portfolio including CopiOs, Regenafil/Regenakit, and bone void fillers for reconstructive and trauma surgery. Competes with GreenBone for hospital formulary slots and orthopedic surgeon adoption across the same indications.

TypeDirect peer
Description

OssDsign is a Swedish med-tech company developing calcium phosphate-based bone graft substitutes (OSSIX Bone, OSSA product family) for cranial and orthopedic applications. Closely comparable to GreenBone in product technology, scale, and European specialty orthobiologics positioning.

TypeBroad incumbent
Description

Medtronic's Spine division markets Infuse (rhBMP-2) and Mastergraft synthetic bone void fillers for spinal fusion and orthopedic trauma. Largest-scale competitor in the bone graft substitute category with unmatched hospital contracts and KOL relationships.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GreenBone Ortho

Orthopedic Bone Regeneration Medical Devicesgreenbone.it

GreenBone Ortho S.p.A. is an Italian medical device company that develops and commercializes b.Bone, a CE-marked biomimetic bone graft substitute made by biomorphically transforming rattan wood into a hydroxyapatite/beta-tricalcium phosphate scaffold. It sells to orthopedic and trauma surgeons and hospitals across Italy, Germany, and Austria via distribution partners.

What GreenBone Ortho does

GreenBone Ortho S.p.A. is an Italian medical device company headquartered in Faenza with manufacturing in Roncadelle, founded in 2014-2015 to commercialize bone graft substitute technology originating from research at ISTEC-CNR (Institute of Science and Technology for Ceramics – National Research Council). The company's sole commercial product is b.Bone, a CE-marked, ISO 10993-compliant bone substitute derived from rattan wood through a patented multi-step biomorphic transformation process that converts the natural wood structure into an inorganic hydroxyapatite/beta-tricalcium phosphate scaffold. The biomimetic 3D porous architecture preserves ion-doped bone-like chemistry (CO32-, Mg2+, Sr2+) and supports osteoinductive bone regeneration, with the product offered in four form factors (cylinders, blocks, wedges, granules) for traumatology, bone augmentation, deformity correction, non-union, osteotomy, and joint revision applications.

The business model is hardware sales of b.Bone medical devices through a hybrid channel: direct field sales to orthopedic surgeons and hospitals supported by clinical evidence generation, plus regional distribution partnerships — Abiogen Pharma and Mikai in Italy, and Endocon for Germany and Austria since September 2024. The company sells to orthopedic and trauma surgeons at hospital procurement level, with its clinical value proposition positioned against autograft (eliminating donor site morbidity) and conventional synthetic bone substitutes. Revenue is not publicly disclosed. The company has raised approximately €27.5 million in equity and non-dilutive funding from META Ventures, Italian Angels for Growth, Innogest Capital, 3B Future Health Fund, CDP Venture Capital, Invitalia Ventures, the European Innovation Council, and a Regione Lombardia grant.

The company is pursuing geographic expansion (DACH, with UK clinical study activity) and indication extension, most notably via the May 2026 AstroBone experiment on the International Space Station — a partnership with ESA, ASI, San Martino Hospital, and the University of Genoa — to test b.Bone behavior in microgravity for osteoporosis treatment. Patient-specific custom-made implants are in development under the Fast-Tech grant. The company holds 11-50 employees, is privately held, and is led by CEO Saverio Gellini with a management team drawn from Medtronic, Invatec, and other medical device backgrounds.

GreenBone Ortho firmographics

Firmographics
Name
GreenBone Ortho
Legal name
GREENBONE ORTHO SPA
Website
https://greenbone.it
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
GreenBone Ortho S.p.A. is an Italian medical device company that develops and commercializes b.Bone, a CE-marked biomimetic bone graft substitute made by biomorphically transforming rattan wood into a hydroxyapatite/beta-tricalcium phosphate scaffold. It sells to orthopedic and trauma surgeons and hospitals across Italy, Germany, and Austria via distribution partners.
Ownership category
akta.pro rank

GreenBone Ortho industry classification

Industry
Product category
Orthopedic Bone Regeneration Medical Devices
NAICS
Dental Equipment and Supplies Manufacturing (339114), Dental Laboratories (339116)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Dental Equipment & Supplies (3843)
akta.pro industry
PRIMARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

Keywords

  • Bone graft substitute
  • Orthopedic medical devices
  • Biomimetic bone implants
  • Bone regeneration scaffolds
  • Hydroxyapatite bone substitute

Where GreenBone Ortho is headquartered

Location

Headquarters

HQ city
Roncadelle
HQ country
Italy
HQ region
Europe

Offices2 records

Markets served

GreenBone Ortho business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. b.Bone Bone Substitute Products: GreenBone Ortho generates revenue through the sale of its b.Bone biomimetic bone substitute products, which are available in multiple forms including cylinders, blocks, wedges, and granules. The products are sold to hospitals and orthopedic surgeons for bone regeneration procedures.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

GreenBone Ortho product offering

Product offering

Core offering

GreenBone Ortho manufactures and sells b.Bone, an innovative biomimetic and bioactive bone substitute derived from rattan wood through a proprietary biomorphic transformation process. The product is composed of hydroxyapatite and beta-tricalcium phosphate in a highly interconnected porous 3D structure that mimics natural human bone architecture. It is available in four form factors (cylinders, blocks, wedges, granules) for orthopedic applications including traumatology, bone augmentation, deformity correction, bone lengthening, non-union treatment, osteotomy, and joint revision.

Product overview

GreenBone Ortho's core offering is the b.Bone product line, a family of biomimetic bone substitute scaffolds derived from rattan wood through a proprietary multi-step biomorphic transformation process. The product portfolio includes four main form factors (cylinders, blocks, wedges, and granules) designed for various orthopedic clinical applications including traumatology, bone augmentation, correction of deformity, bone lengthening, non-union treatment, osteotomy, and joint revision. The technology transforms natural rattan wood into inorganic biomaterial while preserving its hierarchical architecture, creating scaffolds that promote new bone formation and remodeling.

Differentiator

Problem solved

Functional benefit

Brands

  • b.Bone: Innovative biomimetic bone substitute product derived from rattan wood through a patented biomorphic transformation process. CE-marked medical device for bone regeneration in orthopedic procedures.

Products and services

  • b.Bone Bone Substitute b.Bone is an innovative biomimetic and bioactive bone substitute derived from rattan wood through a proprietary biomorphic transformation process. It is composed of hydroxyapatite and beta-tricalcium phosphate in a highly interconnected porous 3D structure that mimics the hierarchical architecture of natural human bone. Available in cylinders, blocks, wedges, and granules, it is used by orthopedic and trauma surgeons for bone regeneration procedures including traumatology, bone augmentation, deformity correction, bone lengthening, non-union treatment, osteotomy, and joint revision.

Quantifiable outcome

  • 75% average bone healing rate at 12 months in LongBone clinical study
  • +4 more outcomes

Companies that use GreenBone Ortho

Customer profile

Named customers5 records

Segments2 records

Ideal customer profiles1 record

GreenBone Ortho technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

GreenBone Ortho partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered key, foundational, project, supporting and minor.

  • EndoconkeyChannel Partner/ Reseller/ Distributor · 10 September 2024Strategic partnership formed September 2024 to bring GreenBone's bone substitute to Germany and Austria. Endocon has deep expertise and strong network in the orthopedic sector.
  • MikaikeyChannel Partner/ Reseller/ Distributor · 9 February 2024Italian distribution partner announced February 2024 for long-term partnership to distribute GreenBone's innovative bone substitute in the Italian market.
  • Abiogen PharmakeyChannel Partner/ Reseller/ Distributor · 1 May 2022Italian distribution partner for b.Bone bone substitute products. Agreement signed May 2022 for distribution in Italian market. Abiogen is specialized in orthopedic and healthcare products.
  • ISTEC-CNR (Institute of Science and Technology for Ceramics – National Research Council)foundationalStrategic or Co-development PartnerResearch institution in Faenza, Italy where the original biomorphic transformation technology was developed by Dr. Anna Tampieri and her team. Dr. Tampieri continues as Board Member of GreenBone.
  • Kayser Space (FAE Technology subsidiary)projectTechnology or IntegrationDesigned and built the sixteen experiment units housing b.Bone scaffold for ISS space experiment. Provided essential infrastructure for survival, growth and monitoring of mesenchymal stem cells in microgravity.
  • ESA (European Space Agency)projectStrategic or Co-development PartnerEuropean Space Agency partnered with GreenBone for AstroBone experiment on International Space Station to test b.Bone behavior in microgravity conditions for osteoporosis research.
  • ASI (Agenzia Spaziale Italiana)projectStrategic or Co-development PartnerItalian Space Agency supporting the AstroBone project alongside ESA for testing b.Bone on ISS for osteoporosis treatment validation.
  • INBAR (International Bamboo and Rattan Organization)supportingStrategic or Co-development PartnerIntergovernmental organization collaborating with GreenBone to promote local partnerships for rattan nursery and proprietary plantations, ensuring environmental sustainability of raw material sourcing.
  • Clinica MobileminorGTM or Marketing PartnerWorldwide partnership announced February 2021 with MotoGP and SuperBike medical team, bringing GreenBone bone substitute to professional motorsport for potential orthopedic applications.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

GreenBone Ortho competitors and assessment

Company assessment

Direct peers

  • Orthofix Medical: Orthofix Medical offers bone growth stimulation devices and orthobiologics (Trinity Elite allograft, FIBERGRAFT) for spine and orthopedic trauma. Closely comparable to GreenBone as a specialty orthobiologics competitor with overlapping indications and channel model.
  • Curasan: Curasan is a German specialty orthobiologics company marketing synthetic bone graft substitutes (Cerasorb) for dental and orthopedic indications. European mid-cap comparable to GreenBone in size, product type, and commercialization stage.
  • Bonesupport: Bonesupport is a Swedish orthobiologics company commercializing CERAMENT, an injectable bone void filler for trauma and orthopedic applications. Directly comparable to GreenBone as a European specialty bone graft substitute player with a single differentiated synthetic technology and CE-marked commercial product.
  • OssDsign: OssDsign is a Swedish med-tech company developing calcium phosphate-based bone graft substitutes (OSSIX Bone, OSSA product family) for cranial and orthopedic applications. Closely comparable to GreenBone in product technology, scale, and European specialty orthobiologics positioning.

Broad incumbents

  • Smith+Nephew: Smith+Nephew markets bone graft substitutes including MAGNEZIUM and HEALOS through its Orthopaedics franchise. Large incumbent with global commercial reach that overlaps with GreenBone's European trauma and reconstruction target indications.
  • Stryker: Stryker's Orthopaedics and Spine segments sell Vitoss, OP-1 Putty, and other bone graft substitutes. Large incumbent with established trauma and reconstructive surgery sales channels that compete head-to-head with b.Bone in hospital procurement cycles.
  • Bioventus: Bioventus is an established orthobiologics company offering bone graft substitutes (including SIGNAFUSE, OSTEOAMP) and osteoarthritis pain treatments. Broader incumbent portfolio overlapping directly with GreenBone's bone graft substitute category, with deeper commercial reach.
  • MTF Biologics: MTF Biologics is a major US tissue bank providing allograft-based bone graft substitutes (including Trinity Evolution, Map3) for orthopedic and sports medicine. Competes with GreenBone in the same orthopedic indications via allograft rather than synthetic route.
  • Zimmer Biomet: Zimmer Biomet offers a broad orthobiologics portfolio including CopiOs, Regenafil/Regenakit, and bone void fillers for reconstructive and trauma surgery. Competes with GreenBone for hospital formulary slots and orthopedic surgeon adoption across the same indications.
  • Medtronic: Medtronic's Spine division markets Infuse (rhBMP-2) and Mastergraft synthetic bone void fillers for spinal fusion and orthopedic trauma. Largest-scale competitor in the bone graft substitute category with unmatched hospital contracts and KOL relationships.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

GreenBone Ortho social profiles

Digital presence

GreenBone Ortho compliance and trust

Trust signal

Compliance2 records

GreenBone Ortho financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GreenBone Ortho leadership team

Management profile

Number of profiles

Profiles9 records

GreenBone Ortho funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GreenBone Ortho M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GreenBone Ortho

What does GreenBone Ortho do?

GreenBone Ortho manufactures and sells b.Bone, an innovative biomimetic and bioactive bone substitute derived from rattan wood through a proprietary biomorphic transformation process. The product is composed of hydroxyapatite and beta-tricalcium phosphate in a highly interconnected porous 3D structure that mimics natural human bone architecture. It is available in four form factors (cylinders, blocks, wedges, granules) for orthopedic applications including traumatology, bone augmentation, deformity correction, bone lengthening, non-union treatment, osteotomy, and joint revision.

Is GreenBone Ortho a public or private company?

GreenBone Ortho is a private company. It is classified as venture growth investor backed and is currently operating.

When was GreenBone Ortho founded?

GreenBone Ortho was founded in 2015. It employs 11 to 50 people.

Where is GreenBone Ortho based?

GreenBone Ortho is headquartered in Roncadelle, Italy, in the Europe region.

How does GreenBone Ortho make money?

One revenue line is on record: b.Bone Bone Substitute Products.

Who are GreenBone Ortho's main competitors?

Direct peers on record are Orthofix Medical, Curasan, Bonesupport and OssDsign. Broad incumbents are Smith+Nephew, Stryker, Bioventus, MTF Biologics, Zimmer Biomet and Medtronic.

Does GreenBone Ortho have an API?

No public API is recorded for GreenBone Ortho.

What industry is GreenBone Ortho in?

GreenBone Ortho's product category is Orthopedic Bone Regeneration Medical Devices. Its primary akta.pro industry code is HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration, with a secondary code of HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM). Its NAICS code is 339114 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinSMEsGreenBone Ortho Raises €8.4M in Funding - FinSMEsGreenBone Ortho, an Italian bio-inspired bone treatment company, raised €8.4M from investors including Helsinn Investment Fund and Invitalia Ventures. The funds will complete clinical development for load-bearing long bone defects, obtain CE Mark, and advance pre-clinical work for other skeletal diseases. The company previously raised €3M in 2015.GlobeNewswireHelsinn Investment Fund leads the financial round in GreenBoneHelsinn Investment Fund led a Euro 2M investment in GreenBone, an Italian bone regeneration technology developer. The funds will support clinical development for load-bearing long bone defects, with a CE Mark target by 2019. GreenBone previously closed a Euro 3M seed round in 2015.FinSMEsGreenBone Raises €3m in Venture Capital FundingGreenBone, a Faenza-based medical device startup, raised €3m in its first venture capital funding from ZernikeMeta Ventures, Italian Angels for Growth, and other angel investors. The company will use the funds to develop its wood-derived bone implant platform, conduct clinical studies on patients with bone damage, and obtain the CE mark.BeBeezGreenBone raccoglie 3 mln da Zernike e dagli angeli IAGGreenBone, a Faenza-based medical startup, raised €3 million in a first funding round from ZernikeMeta Ventures and angel investors. The company develops bone implants from natural structures like wood for orthopedic trauma. The technology is in preclinical study, with a planned clinical phase.